Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TexaClear Allergy Relief is an approved over-the-counter (OTC) fixed-dose combination drug developed and marketed by GM Pharmaceuticals. It contains chlophedianol hydrochloride, a centrally acting non-opioid cough suppressant, and pyrilamine maleate, a first-generation antihistamine. The drug is indicated for the temporary relief of mild to severe allergy symptoms, including sneezing, runny nose, watery eyes, itchy nose and throat, and allergy cough due to the common cold, hay fever, or other upper respiratory allergies. It is available in both liquid and tablet forms and is formulated to be free from dyes, alcohol, gluten, sugar, and acetaminophen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlophedianol + pyrilamine.